Amanda Teeple
Janssen Pharmaceutica
24 Papers
17 Citations
Amanda Teeple is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Medicine & Psoriasis. The author has an hindex of 4, co-authored 14 publications.
Chat about Author
Papers
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
Amanda M. Johnson,Maria Barsky,Waseem Ahmed,Samantha Zullow,Jonathan S. Galati,Vipul Jairath,Neeraj Narula,Farhad Peerani,Benjamin H. Click,Elliot Coburn,ThucNhi T. Dang,Stephanie Gold,Manasi Agrawal,Rajat Garg,Manik Aggarwal,D Mohammad,Brendan P. Halloran,Gursimran Kochhar,Hannah Todorowski,Nabeeha Mohy Ud Din,James L. Izanec,Amanda Teeple,Christopher Gasink,Erik Muser,Zhijie Ding,Arun Swaminath,Komal Lakhani,Daniel T. Hogan,Samit K. Datta,Ryan C. Ungaro,Brigid S. Boland,Matthew Bohm,Monika Fischer,Sashidhar Sagi,Anita Afzali,Thomas A. Ullman,Garrett Lawlor,Daniel C. Baumgart,Shannon Chang,David Hudesman,Dana J. Lukin,Ellen Scherl,Jean-Frederic Colombel,Bruce E. Sands,Corey A. Siegel,Miguel Regueiro,William J. Sandborn,David H. Bruining,Sunanda V. Kane,Edward V. Loftus,Parambir S. Dulai +50 more
TL;DR: The greatest treatment effect of UST was seen in bio-naive patients, and dose escalation may recapture clinical response, with 40% of patients from a highly refractory cohort achieving clinical remission by 12 months.
40
The economic burden of psoriasis with high comorbidity among privately insured patients in the United States
Dominic Pilon,Amanda Teeple,Masha Zhdanava,Martin Ladouceur,Hoi Ching Cheung,Erik Muser,Patrick Lefebvre +6 more
TL;DR: HRU and cost burden of psoriasis are substantial, and increase with the development of Psoriasis-related comorbidities.
28
Prevalence and economic burden of comorbid anxiety and depression among patients with moderate-to-severe psoriasis.
TL;DR: The prevalence of psychiatric disorders is higher among PsO patients than the general population, and the incremental burden of treated anxiety/depression is substantial.
23
Treatment Adherence and Persistence of Seven Commonly Prescribed Biologics for Moderate to Severe Psoriasis and Psoriatic Arthritis in a U.S. Commercially Insured Population.
TL;DR: In this paper, the authors examined adherence and persistence among patients with comorbid psoriasis and psoriatic arthritis who initiated treatment with any of the seven biologics, i.e., Adalimumab (ADA), certolizumab pegol (CER), etanercept (ETA), guselkumab (GUS), ixekizumaab (IXE), secukinumab(SEC), and ustekinumax (UST), which are all FDA-approved for the treatment of psor
16
Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population.
TL;DR: Although heterogeneity across cohorts may explain some medication utilization differences, ustekinumab was associated with lower discontinuation and greater persistence and adherence.
16